Niagen Bioscience Reports Strong Q2 Sales Growth

Niagen Bioscience ( (NAGE) ) has provided an update.

On August 6, 2025, Niagen Bioscience reported a 37% increase in net sales to $31.1 million for the second quarter of 2025, with a net income of $3.6 million. The company also raised its full-year revenue outlook, expecting growth between 22% and 27%, driven by strong sales of Tru Niagen® and Niagen® ingredients. Recent operational highlights include the completion of the Phase III NOPARK trial for Parkinson’s disease and a partnership with Haukeland University Hospital. The company also expanded its presence in luxury hospitality and wellness clinics, reflecting its strategic focus on growth and innovation in the NAD+ market.

The most recent analyst rating on (NAGE) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Niagen Bioscience stock, see the NAGE Stock Forecast page.

Spark’s Take on NAGE Stock

According to Spark, TipRanks’ AI Analyst, NAGE is a Outperform.

Niagen Bioscience’s strong financial performance and positive earnings call sentiment are major strengths, indicating robust growth and profitability. However, technical analysis reveals bearish momentum, and the high P/E ratio suggests potential overvaluation. These factors collectively result in a moderate overall stock score.

To see Spark’s full report on NAGE stock, click here.

More about Niagen Bioscience

Niagen Bioscience, Inc. operates in the biotechnology industry, focusing on the development and commercialization of nicotinamide riboside (Niagen®) products. The company is a leader in the expanding NAD+ market, offering products such as Tru Niagen® and Niagen® ingredients for both consumer and pharmaceutical applications.

Average Trading Volume: 1,086,350

Technical Sentiment Signal: Buy

Current Market Cap: $721.5M

See more insights into NAGE stock on TipRanks’ Stock Analysis page.